Explore 3 Stock Ideas & Industry Insights Download Free Report

News

State Street Reports 5.6% Stake in Intellia Therapeutics

State Street Corporation filed a Schedule 13G with the SEC on November 10, 2026, disclosing beneficial ownership of 7,809,060 shares of Intellia Therapeutics Inc common stock as of September 30, 2026.

Nitish Kishor | 10 November 2026

State Street Reports 4.8% Stake in Iovance Biotherapeutics

State Street Corporation filed a Schedule 13G with the SEC on November 10, 2026, disclosing beneficial ownership of 21,695,003 shares of Iovance Biotherapeutics Inc common stock as of September 30, 2026.

Manish Choudhary | 10 November 2026

State Street Discloses 6.5% Stake in International Paper

State Street Corporation filed a Schedule 13G with the SEC on November 10, 2026, disclosing beneficial ownership of 34,166,190 shares of International Paper Co common stock as of September 30, 2026.

Anjali Anand | 10 November 2026

State Street Reports 5% Stake in Intuitive Machines

State Street Corporation filed a Schedule 13G with the SEC on November 9, 2026, disclosing beneficial ownership of 8,656,543 shares of Intuitive Machines Inc common stock as of September 30, 2026.

Nitish Kishor | 10 November 2026

MaxCyte to Acquire Akron BioProducts for $105M Cash Plus Stock

MaxCyte, Inc. filed an 8-K with the SEC on November 10, 2026, disclosing that it entered into a Securities Purchase Agreement on November 9, 2026, to acquire all outstanding equity interests of Akron BioProducts LLC from affiliates of Arcline Investment Management.

Aditi Sarkar | 10 November 2026

State Street Discloses 5.9% Stake in indie Semiconductor

State Street Corporation filed a Schedule 13G with the SEC on November 9, 2026, disclosing beneficial ownership of 12,902,835 shares of indie Semiconductor Inc common stock, representing 5.9% of the class, as of September 30, 2026.

Shwetambri Chauhan | 10 November 2026

Tyra Biosciences Posts $135.985M Nine-Month Net Loss

Tyra Biosciences, Inc. filed its quarterly report on Form 10-Q with the SEC on November 10, 2026, covering the fiscal quarter and nine months ended September 30, 2026, disclosing a net loss of $135.985 million for the nine-month period and reporting total assets of …

Nitish Kishor | 10 November 2026

Cingulate Plans CTx-1301 NDA Resubmission by January 2027

Cingulate Inc. filed a Form 8-K on November 10, 2026, disclosing the status of its CTx-1301 new drug application resubmission following an FDA Complete Response Letter, with a resubmission window targeted between December 2026 and January 2027.

Aakashdeep | 10 November 2026

Coursera Cuts 10% of Workforce After Udemy Merger

Coursera, Inc. filed a Form 8-K on November 10, 2026, disclosing a workforce reduction plan committed on November 9, 2026, in connection with its merger integration with Udemy, Inc.

Vinay Lochav | 10 November 2026

Coya Therapeutics Q3 2026: Net Loss Widens to $10.6M

Coya Therapeutics, Inc. filed its Form 10-Q for the quarterly period ended September 30, 2026 with the U.S. Securities and Exchange Commission on November 10, 2026, reporting financial results for the three and nine months ended that date.

Aditi Sarkar | 10 November 2026
Support

Hi! How can we help you today?

Loading…